title: High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
abstract: High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) has improved response rates and survival for patients with multiple myeloma (MM). We report a single-institution experience using two conditioning regimens, busulfan, cyclophosphamide, and etoposide (BCV) or high-dose melphalan (HDM). Between July 1992 and August 2003, 110 patients with MM (median age=56.1) underwent HDC with ASCT using either BCV (n=62) or HDM (n=48) in sequential cohorts as the preparative regimen. Overall response rates, progression-free survival, and median overall survival were similar. BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, Starling-Loving Hall, Columbus, OH 43210, USA. don.benson@osumc.edu
authors.forename: Don M
authors.initials: DM
authors.lastname: Benson
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Elder
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Lin
authors.forename: William
authors.initials: W
authors.lastname: Blum
authors.forename: Sam
authors.initials: S
authors.lastname: Penza
authors.forename: Belinda
authors.initials: B
authors.lastname: Avalos
authors.forename: Edward
authors.initials: E
authors.lastname: Copelan
authors.forename: Sherif S
authors.initials: SS
authors.lastname: Farag
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002066:Busulfan / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000503:physiopathology / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D015996:Survival Rate; D014182:Transplantation, Autologous
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D003520:Cyclophosphamide; D002066:Busulfan; D008558:Melphalan